NHTSA Discloses Volkswagen to Recall Vehicles at Risk of Unexpectedly Opening Doors — Update
By Denny Jacob
U.S. auto-safety regulators disclosed that Volkswagen Group of America will recall certain vehicles after finding their door handles may allow water to enter the circuit board assembly, which can cause the doors to open unexpectedly.
The National Highway Traffic Safety Administration said Volkswagen is recalling certain ID.4 vehicles from 2021 to 2024. The estimated percentage of vehicles with a defect is about 1%, according to a report from the regulator.
Volkswagen isn't aware of any crashes or injuries as a result of the issue, according to the report.
"Volkswagen has notified NHTSA of a voluntary safety recall affecting approximately 98,806 MY 2021-2024 VW ID.4 vehicles," said the carmaker. "ID.4 vehicles may have been built with door handles that did not conform to our specifications for waterproofing."
NHTSA said Volkswagen dealers will inspect and replace the door handles as necessary, and update the vehicle software, free of charge. Owner notification letters are expected to be mailed Nov. 1, it added.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
September 10, 2024 13:35 ET (17:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks